We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
UK genomic sequencing group ‘not ruling out’ any options, says chief executive
Companies want incentives to create jobs and stave off competition from China
With the latest credit for research intensive businesses, the government is picking winners by the back door
Company’s shares jump after activist investor launches proxy battle
US pharma group to pay $229 a share in cash deal that signals rebound in M&A activity
Therapies based on editing of human genomes predicted to have a price tag of $2mn per patient
The ability to apply massive computing power to DNA is causing concern over biological warfare
Data businesses and medical equipment suppliers are riding long-term trends such as ageing
DNA sequencing expert’s investors question acquisition of cancer testing group that has also angered EU regulators
Beijing’s push to boost the sector has been undermined by reimbursement rules
Executives have funding and strategic need for M&A but few are confident to press ahead
Covid vaccine maker looks to use machine learning to help discover new treatments
Agreement is one of several announced as major healthcare conference begins in San Francisco
Covid-19 vaccine maker hails ‘huge’ investment aimed at recruiting 10,000 participants with NHS
Former Johnson & Johnson executive ‘on the look out’ for rivals amid biotech sell-off
CSL’s $3.5mn single-dose treatment for haemophilia sparks debate over how to pay for revolutionary drugs
California-based biotech wins three-way race to secure new drugs pipeline
Drugmakers seek to replenish pharmaceuticals pipelines amid broader slowdown in transactions
Northwest Biotherapeutics claims Citadel Securities, Virtu and others drove down its share price
Ending of pharma group’s IP truce spells fight for future of mRNA technology
Jab maker ties weaker revenue outlook to delivery delays and manufacturing issues
Verge says ALS therapy is one of the first to be developed by a tech-enabled platform
Companies look for alternative sources of funds after share sell-off
Valuations soared in the pandemic and then crashed, but more promising start-ups are managing to raise funds
Despite pledges to learn the lessons of Covid-19, caution is already waning. Plus: crisis turned a spotlight on healthcare services; climate change and urbanisation drive rise in ‘zoonotic’ illnesses; return of polio to US highlights impact of anti-vax campaigners
International Edition
